306 Publications (Page 9 of 13)
2004
P4-073 CDC2 gene polymorphism is associated with cognitive decline in Alzheimer's disease
Faltraco, Frank⋅Teipel, Stefan J⋅Dodel, Richard⋅Du, Yansheng⋅Farlow, Martin R⋅Shen, Yong⋅Moeller, Hans-Juergen and Hampel, Harald
Neurobiology of Aging, vol. 25, pp. S495, 2004. | Journal Article
 
Utilizing combination therapy in the treatment of Alzheimer's disease.
Farlow, Martin R
Expert review of neurotherapeutics. , vol. 4, (no. 5), pp. 799-808, 2004/Sep. | Journal Article
2003
A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer's disease
Cummings, Jeffrey L⋅Farlow, Martin R⋅Geda, Yonas E⋅McPherson, Susan⋅Marin, Deborah B⋅Petersen, Ronald C⋅Smith, Glenn E⋅Spoor, Eleanor⋅Sunderland, Trey⋅Zubenko, George S and Zubenko, Wendy N
American Journal of Psychiatry, vol. 160, (no. 4), pp. 857-866, 2003. | Journal Article
 
A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer's disease.
Zubenko, George S⋅Zubenko, G.S.⋅Zubenko, W.N.⋅Zubenko, Wendy N⋅McPherson, Susan⋅McPherson, S.⋅Spoor, Eleanor⋅Spoor, E.⋅Marin, D.B.⋅Marin, Deborah B⋅Farlow, Martin R⋅Farlow, M.R.⋅Smith, Glenn E⋅Smith, G.E.⋅Geda, Yonas E⋅Geda, Y.E.⋅Cummings, Jeffrey L⋅Cummings, J.L.⋅Petersen, R.C.⋅Petersen, Ronald C⋅Sunderland, T. and Sunderland, Trey
The American journal of psychiatry. , vol. 160, (no. 5), pp. 857-66, 2003/May. | Journal Article
 
A Critical Analysis of New Molecular Targets and Strategies for Drug Developments in Alzheimer's Disease
Lahiri, Debomoy K⋅Farlow, Martin R⋅Sambamurti, Kumar⋅Greig, Nigel H⋅Giacobini, E. and Schneider, Lon S
Current Drug Targets, vol. 4, (no. 2), pp. 97-112, 2003. | Journal Article
 
A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin) in mild Alzheimer's disease patients
Grundman, Michael⋅Capparelli, E.⋅Kim, HT⋅Morris, John C⋅Farlow, Martin R⋅Rubin, Eugene H⋅Heidebrink, Judith L⋅Hake, A.⋅Ho, G.⋅Schultz, AN⋅Schafer, K.⋅Houston, Wesley⋅Thomas, R. and Thal, Leon J
Life Sciences, vol. 73, (no. 5), pp. 539-553, 2003. | Journal Article
 
Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial
Farlow, Martin R⋅Potkin, Steven G⋅Koumaras, Barbara⋅Veach, Jeffrey and Mirski, Dario
Archives of Neurology, vol. 60, (no. 6), pp. 843-8, Jun 2003. | Journal Article
 
Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?
Clark, Christopher M⋅Xie, Sharon X⋅Chittams, Jesse⋅Ewbank, Douglas C⋅Peskind, Elaine R⋅Galasko, Douglas R⋅Morris, John C⋅Mc Keel, Daniel W⋅Farlow, Martin R⋅Weitlauf, Sharon L⋅Quinn, Joseph F⋅Kaye, Jeff⋅Knopman, David S⋅Arai, Hiroyuki⋅Doody, Rachelle S⋅De Carli, Charles D⋅Leight, Susan⋅Lee, Virginia M and Trojanowski, John Q
Archives of Neurology, vol. 60, (no. 12), pp. 1696-702, 2003/Dec. | Journal Article
 
Clinical pharmacokinetics of galantamine.
Farlow, Martin R
Clinical pharmacokinetics. , vol. 42, (no. 15), pp. 1383-92, 2003. | Journal Article
 
Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
Aisen, Paul S⋅Schafer, Kimberly A⋅Grundman, Michael⋅Pfeiffer, Eric⋅Sano, Mary⋅Davis, Kenneth L⋅Farlow, Martin R⋅Jin, Shelia⋅Thomas, Ronald G and Thal, Leon J
JAMA : the journal of the American Medical Association. , vol. 289, (no. 21), pp. 2819-26, 2003/Jun/4. | Journal Article
 
Human anti-[beta]-amyloid antibodies block [beta]-amyloid fibril formation and prevent [beta]-amyloid-induced neurotoxicity
Du, Yansheng⋅Wei, Xing⋅Dodel, Richard⋅Sommer, Norbert⋅Hampel, Harald⋅Gao, Feng⋅Ma, Zhizhong⋅Zhao, Liming⋅Oertel, Wolfgang H and Farlow, Martin R
Brain, vol. 126, (no. 9), pp. 1935-9, Sep 2003. | Journal Article
 
Minocycline blocks 6-hydroxydopamine-induced neurotoxicity and free radical production in rat cerebellar granule neurons
Lin, S.⋅Wei, X.⋅Xu, Y.⋅Yan, C.⋅Dodel, R.⋅Zhang, Y.⋅Liu, J.⋅Klaunig, James E⋅Farlow, Martin R and Du, Yansheng
Life Sciences, vol. 72, (no. 14), pp. 1635-1641, 2003. | Journal Article
 
Review: cholinesterase inhibitors have a modest effect on neuropsychiatric and functional outcomes in Alzheimer's disease
Lahiri, Debomoy K⋅Lahiri, Debomoy K⋅Farlow, Martin R and Farlow, Martin R
Evidence-based mental health, vol. 6, (no. 3), pp. 94, 2003-Aug. | Journal Article
 
Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors.
Gauthier, Serge⋅Emre, Murat⋅Farlow, Martin R⋅Bullock, Roger⋅Grossberg, George T and Potkin, Steven G
Current medical research and opinion, vol. 19, (no. 8), pp. 707-14, 2003. | Journal Article
 
Update on rivastigmine.
Farlow, Martin R
The neurologist. , vol. 9, (no. 5), pp. 230-4, 2003/Sep. | Journal Article
2002
A clinical overview of cholinesterase inhibitors in Alzheimer's disease.
Farlow, Martin R
International psychogeriatrics / IPA. , vol. 14 Suppl 1, pp. 93-126, 2002. | Journal Article
 
A Phase I Study of AIT-082 in Healthy Elderly Volunteers
Grundman, Michael⋅Farlow, Martin R⋅Peavy, G.⋅Kim, HT⋅Capparelli, E.⋅Schultz, AN⋅Salmon, David P⋅Ferris, Steven H⋅Mohs, Richard C⋅Thomas, Ronald G⋅Schafer, K.⋅Campbell, K.⋅Hake, AM⋅Schoos, B. and Thal, Leon J
Journal of Molecular Neuroscience, vol. 18, (no. 3), pp. 283-293, 2002. | Journal Article
 
A polymorphism in the cystatin C promoter region is not associated with an increased risk of AD.
Dodel, R C⋅Du, Yansheng⋅Depboylu, C⋅Kurz, A⋅Eastwood, B⋅Farlow, Martin R⋅Oertel, W H⋅Müller, U and Riemenschneider, M
Neurology, vol. 58, (no. 4), pp. 664, 2002/Feb/26. | Journal Article
 
Cholinesterase inhibitors: relating pharmacological properties to clinical profiles: Introduction.
Farlow, Martin R
International journal of clinical practice. Supplement, (no. 127), pp. 1-5, 2002/Jun. | Journal Article
 
Current drug targets for Alzheimer's disease treatment
Lahiri, Debomoy K⋅Lahiri, Debomoy K⋅Farlow, Martin R⋅Farlow, Martin R⋅Greig, Nigel H⋅Greig, Nigel H⋅Sambamurti, Kumar and Sambamurti, Kumar
Drug Development Research, vol. 56, (no. 3), pp. 281, July 2002. | Journal Article
 
Do cholinesterase inhibitors slow progression of Alzheimer's disease?
Farlow, Martin R
International journal of clinical practice. Supplement, (no. 127), pp. 37-44, 2002/Jun. | Journal Article
 
Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease.
Dodel, Richard⋅Hampel, Harald⋅Depboylu, Candan⋅Lin, Suizhen⋅Gao, Feng⋅Schock, Sabine⋅Jäckel, Steffi⋅Wei, Xing⋅Buerger, Katharina⋅Höft, Christine⋅Hemmer, Bernhard⋅Möller, Hans-Jürgen⋅Farlow, Martin R⋅Oertel, Wolfgang H⋅Sommer, Norbert and Du, Yansheng
Annals of Neurology, vol. 52, (no. 2), pp. 253-6, 2002/Aug. | Journal Article
 
NF-kappaB mediates IL-1beta-induced synthesis/release of alpha2-macroglobulin in a human glial cell line.
Gao, Feng⋅Gao, Feng⋅Bales, Kelly R⋅Bales, Kelly R⋅Dodel, Richard C⋅Dodel, Richard C⋅Liu, Junyi⋅Liu, Junyi⋅Chen, Xianming⋅Chen, Xianming⋅Hample, Harald⋅Hample, Harald⋅Farlow, Martin R⋅Farlow, Martin R⋅Paul, Steven M⋅Paul, Steven M⋅Du, Yansheng and Du, Yansheng
Brain research. Molecular brain research, vol. 105, (no. 1-2), pp. 108-14, 2002/Sep/30. | Journal Article
 
NF- Kappa B mediates IL-1 beta -induced synthesis/release of alpha 2-macroglobulin in a human glial cell line
Gao, F.⋅Bales, KR⋅Dodel, RC⋅Liu, J.⋅Chen, X.⋅Hample, H.⋅Farlow, Martin R⋅Paul, SM and Du, Yansheng
Molecular Brain Research, vol. 105, (no. 1-2), pp. 108-114, 2002. | Journal Article
 
NF-κB mediates IL-1β-induced synthesis/release of α2-macroglobulin in a human glial cell line
Gao, Feng⋅Gao, Feng⋅Bales, Kelly R⋅Bales, Kelly R⋅Dodel, Richard C⋅Dodel, Richard C⋅Liu, Junyi⋅Liu, Junyi⋅Chen, Xianming⋅Chen, Xianming⋅Hample, Harald⋅Hample, Harald⋅Farlow, Martin R⋅Farlow, Martin R⋅Paul, Steven M⋅Paul, Steven M⋅Du, Yansheng and Du, Yansheng
Molecular Brain Research, vol. 105, (no. 1-2), pp. 114, 2002-09-00. | Journal Article